The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.

Inclusion Criteria:

• Documented colorectal cancer which is EGFR-positive and is metastatic.
• Prior irinotecan, alone or in combination, as first-line treatment of metastatic disease.

Exclusion Criteria:

• A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy.
• Known dihydropyrimidine dehydrogenase (DPD) deficiency.
• Known metastases in the central nervous system.
• Symptomatic sensory or peripheral neuropathy.
• More than one prior chemotherapy regimen for the treatment of metastatic colorectal cancer.
• Prior oxaliplatin therapy.
• Prior cetuximab or other therapy which targets the EGF pathway.
• Prior chimerized or murine monoclonal antibody therapy.